Navigation Links
Clinical Comparisons Between ADHD Drugs Are Less

Research has shown that there are few clinical comparisons available between the drugs for ADHD. As a result, parents seeking the best individual drug for their children with attention deficit hyperactivity disorder // have little hard evidence to help make that choice.

There are few head-to-head clinical comparisons of many ADHD medications, despite the relatively large variety of drugs prescribed for ADHD and the prevalence of the condition among children and adults, according to a new review from the Oregon Evidence-based Practice Center at the Oregon Health and Science University.

The Oregon Evidence-based Practice Center makes available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes.

The majority of the head-to-head trials identified by the Oregon reviewers compared the widely prescribed ADHD medication Ritalin with other drugs. Most of these comparative trials were short in duration, included only a small number of patients and did not measure the long-term effects of the drugs.

As for safety, the researchers found that short-term, randomized controlled trials do not provide clear evidence that any one stimulant is any more tolerable than another or that non-stimulants are more tolerable than stimulants.

None of the trials compared how well the drugs performed in terms of improving academic performance, quality of life or social skills, the researchers found.

Stimulant medications such as Ritalin and amphetamines are most often prescribed for ADHD, but the Oregon study includes several types of ADHD medications that have never been examined before in a systematic review, including newer stimulants such as modafinil and non-stimulant drugs such as Strattera (atomoxetine), antihypertensive drugs such as guanfacine and older antipsychotic drugs such as clozapine.

Limited evidence suggests that the antihypertensive dr ugs clonidine and guanfacine reduce the severity of facial tics in children with ADHD, but the two drugs are not approved by the Food and Drug Administration for the treatment of ADHD.

Source: Newswise
'"/>




Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. A Novel System For Clinical Banking Of Umbilical Cord Blood
5. Clinical Renal Trails Do Not Have Sufficient Women Participants
6. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Sue Desmond-Hellmann, ... Class of 2016 to stretch the limits of human possibility in her keynote address ... p.m. in the Georgia Dome. , Drawing on her rich experience as a scientist, ...
(Date:5/3/2016)... ... , ... Calvary Hospital recently hosted a reception to mark a new music ... at Mary, Manning Walsh Home (MMW) in Manhattan. , During the school year, ... hour, once a week. The music brings a lot of joy to the patients, ...
(Date:5/3/2016)... NJ (PRWEB) , ... May 03, 2016 , ... ... BCBSNJ) today announced that it has been honored as one of the nation’s ... the 2016 InformationWeek Elite 100. Horizon received the recognition for technology achievements that ...
(Date:5/3/2016)... Springs, FL (PRWEB) , ... May 03, 2016 ... ... nation’s leading innovative specialty pharmacies, will be represented at the 2016 Asembia ... Las Vegas. The Asembia Summit is the largest U.S. health care conference for ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean ... launching a new client service center in La Vergne, Tennessee, near Nashville. The ... the full range of Empyrean client services. , “Our Nashville-area center allows us ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 BioNovus ... Center,s Institute for Advancing Medical Innovation (IAMI) today ... new drugs, diagnostics and medical devices. ... Innovations with rights to license, develop and commercialize ... "This partnership represents a significant ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)...  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease ... ... ... ... ...
Breaking Medicine Technology: